Hillstream BioPharma (HILS) announced the expansion of its collaboration with Minotaur Therapeutics and its license agreement with OmniAb (OABI) to advance the development of next generation targeted Knob biologics against HER3 and a new undisclosed oncology target. Hillstream will collaborate with Minotaur using OmniAb’s “OmniTaur” technology to discover targeted biotherapeutic Picobodies complementing Hillstream’s most advanced program, HSB-3215, a HER2/HER3 bispecific antibody. Randy Milby, Chief Executive Officer of Hillstream, stated, “We are extremely pleased with the progress made to date. The Knob biologics program continues to be a great addition to our portfolio as we rapidly progress our lead asset HSB-3215 towards an IND. Hillstream is now poised to develop a novel technology for creating multiple proteins to enhance targeted cancer immunotherapy.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HILS:
- Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215
- Hillstream BioPharma downgraded to Neutral from Buy at Dawson James
- Hillstream BioPharma appoints Sireesh Appajosyula as COO
- Hillstream BioPharma announces strategic reprioritization of pipeline
- Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics